Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "AA (arachidonic acid) is the precursor of both prostaglandin E2 (PGE2) and LXA4 suggesting that AA (arachidonic acid) is most suited for such preventive and therapeutic approach." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.